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Summary
Background The Xpert MTB/RIF test (Cepheid, Sunnyvale, CA, USA) can detect tuberculosis and its multidrug-
resistant form with very high sensitivity and speciﬁ city in controlled studies, but no performance data exist from 
district and subdistrict health facilities in tuberculosis-endemic countries. We aimed to assess operational feasibility, 
accuracy, and eﬀ ectiveness of implementation in such settings.
Methods We assessed adults (≥18 years) with suspected tuberculosis or multidrug-resistant tuberculosis consecutively 
presenting with cough lasting at least 2 weeks to urban health centres in South Africa, Peru, and India, drug-resistance 
screening facilities in Azerbaijan and the Philippines, and an emergency room in Uganda. Patients were excluded 
from the main analyses if their second sputum sample was collected more than 1 week after the ﬁ rst sample, or if no 
valid reference standard or MTB/RIF test was available. We compared one-oﬀ  direct MTB/RIF testing in nine 
microscopy laboratories adjacent to study sites with 2–3 sputum smears and 1–3 cultures, dependent on site, and drug-
susceptibility testing. We assessed indicators of robustness including indeterminate rate and between-site performance, 
and compared time to detection, reporting, and treatment, and patient dropouts for the techniques used.
Findings We enrolled 6648 participants between Aug 11, 2009, and June 26, 2010. One-oﬀ  MTB/RIF testing detected 933 
(90·3%) of 1033 culture-conﬁ rmed cases of tuberculosis, compared with 699 (67·1%) of 1041 for microscopy. MTB/RIF 
test sensitivity was 76·9% in smear-negative, culture-positive patients (296 of 385 samples), and 99·0% speciﬁ c 
(2846 of 2876 non-tuberculosis samples). MTB/RIF test sensitivity for rifampicin resistance was 94·4% (236 of 250) 
and speciﬁ city was 98·3% (796 of 810). Unlike microscopy, MTB/RIF test sensitivity was not signiﬁ cantly lower in 
patients with HIV co-infection. Median time to detection of tuberculosis for the MTB/RIF test was 0 days (IQR 0–1), 
compared with 1 day (0–1) for microscopy, 30 days (23–43) for solid culture, and 16 days (13–21) for liquid culture. 
Median time to detection of resistance was 20 days (10–26) for line-probe assay and 106 days (30–124) for conventional 
drug-susceptibility testing. Use of the MTB/RIF test reduced median time to treatment for smear-negative tuberculosis 
from 56 days (39–81) to 5 days (2–8). The indeterminate rate of MTB/RIF testing was 2·4% (126 of 5321 samples) 
compared with 4·6% (441 of 9690) for cultures.
Interpretation The MTB/RIF test can eﬀ ectively be used in low-resource settings to simplify patients’ access to early 
and accurate diagnosis, thereby potentially decreasing morbidity associated with diagnostic delay, dropout and 
mistreatment.
Funding Foundation for Innovative New Diagnostics, Bill & Melinda Gates Foundation, European and Developing 
Countries Clinical Trials Partnership (TA2007.40200.009), Wellcome Trust (085251/B/08/Z), and UK Department for 
International Development.
Introduction
Two of the three key infectious diseases of man, HIV and 
malaria, can be diagnosed in primary-care settings with 
straightforward rapid tests. No such technology has been 
available to accurately detect tuberculosis and its drug-
resistant forms, and this absence has been a major 
obstacle to improvement of tuberculosis care and 
reduction of the global burden of disease. Microscopy 
alone, although inexpensive, misses many patients and 
detects only those with relatively advanced disease.1–3 
Presently, only 28% of expected incident cases of 
tuberculosis are detected and reported as smear positive.4 
Undetected cases of disease increase morbidity, mortality, 
and disease transmission.5–7 In many countries, epidemic 
HIV infection has further reduced the sensitivity of 
microscopy and increased the necessity of rapid diagnosis 
of tuberculosis. The mortality of untreated or mistreated 
tuberculosis in people with advanced HIV is high.8–10 
Autopsy studies in various countries have shown that 
30–60% of people with HIV infection may die with 
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tuberculosis, often undiagnosed, moving the cure-rate 
target of 85% for tuberculosis out of reach unless 
available diagnostic technologies can be improved.11,12
Multidrug-resistant tuberculosis is an increasing 
concern globally and directly threatens disease-control 
eﬀ orts in many countries.13 Only 30 000 of nearly 
500 000 new cases of multidrug-resistant tuberculosis 
every year13 are detected and reported,4 and misdiagnosis 
causes thousands of deaths, nosocomial and community 
transmission, and ampliﬁ cation of drug resistance.14–16
In recognition of these issues, substantial eﬀ orts are 
being made to strengthen laboratory capacity to diagnose 
smear-negative and multidrug-resistant tuberculosis, 
including increased use of solid and liquid culture, 
conventional drug-susceptibility testing, and line-probe 
assays. Unfortunately, these tests require extensive 
laboratory infrastructure and cannot be done outside of 
reference facilities.
Recently, a real-time PCR assay for Mycobacterium 
tuberculosis that simultaneously detects rifampicin 
resistance was developed on the GeneXpert platform 
(Cepheid, Sunnyvale, CA, USA), which integrates sample 
processing and greatly simpliﬁ es testing.17,18 This assay, 
Xpert MTB/RIF, showed excellent performance in a 
multicentre study19 undertaken in reference laboratories. 
In the study,19 one-oﬀ  direct MTB/RIF testing detected 
92·2% of cases of pulmonary tuberculosis, including 
72·5% of those with smear-negative disease, which was 
equivalent to that reported for solid culture.
Diagnostic tests often do well in initial studies that are 
usually done in near-ideal settings in reference labora-
tories; however, performance is frequently reduced 
when assays are tested in settings of intended use. In 
our study, we aimed to establish whether the MTB/RIF 
test was robust enough to retain high accuracy when 
used in district and subdistrict health facilities in 
resource-poor countries, and to measure the operational 
feasibility and eﬀ ectiveness of its implementation in 
such settings.
Methods
Study population
In our multicentre implementation study, we enrolled 
adults aged 18 years or older with at least 2 weeks of 
cough who presented consecutively to urban or 
periurban primary-care health centres in South Africa, 
Peru, and India, to drug-resistance screening facilities 
in Azerbaijan and the Philippines, and to an emergency 
room at a central hospital in Uganda, and provided at 
least two sputum samples. Patients were excluded from 
the main analyses if their second sputum sample was 
collected more than 1 week after the ﬁ rst sample, if no 
culture was done, or if there was no valid culture, no 
valid MTB/RIF test result, smear-positive with no 
positive cultures, only one positive culture with 20 or 
fewer colonies for solid culture or more than 28 days to 
positivity for liquid culture, a positive culture during 
follow-up only, only one positive culture with missing 
speciation result, a positive culture with only non-
tuberculous mycobacterial growth, or discrepant 
rifampicin results by conventional drug-susceptibility 
testing on two samples.
We established the MTB/RIF test in the microscopy 
area of nine laboratories that were located within the 
same building at eight sites or a nearby building at one 
site (in one of two sites in Cape Town, South Africa). We 
chose study sites to represent diverse populations of 
patients and laboratory capacities. Sites in South Africa 
and Uganda served populations with a high prevalence 
of HIV, centres in Peru and India served populations 
with low prevalence of HIV and multidrug-resistant 
tuberculosis, and sites in Azerbaijan and the Philippines 
served populations with a high prevalence of multidrug-
resistant tuberculosis.
The study was endorsed by national tuberculosis 
programmes of participating countries and approved 
by nine governing institutional review boards. The 
requirement to obtain individual informed consent was 
waived by all institutional review boards.
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Lima, Peru Baku, Azerbaijan Kampala, Uganda Vellore, India Manila, Philippines Cape Town, South Africa
Routine smear 
microscopy and 
MTB/RIF test
In parallel In parallel In parallel In parallel In parallel Weekly alternation 
Number of sputum 
samples
2 (spot, morning) 3 (spot, spot, spot) 3 (spot, spot, morning) 2 (spot, morning) 3 (spot, morning, spot) 2 (spot, morning)
Direct MTB/RIF test Sp 2 (morning) Sp 1 (spot) Sp 1 (spot) Sp 2 (morning) Sp 1 (spot) Sp 1 (spot)
Routine smear 
microscopy
2 direct ZN (Sp 1, Sp2) 3 direct ZN (Sp 1, Sp2, Sp3) 2 direct ZN (Sp 1, Sp2) 2 direct ZN (Sp 1, Sp2) 3 direct ZN (Sp 1, Sp2, Sp3) 2 FM on pellet (Sp 1, Sp2)*
Culture method 1 MGIT  (Sp 1) 1 MGIT, 1 LJ (Sp 2) 1 MGIT (Sp 2), 2 LJ (Sp 2, 
Sp3)
1 LJ (Sp 1) 1 MGIT (Sp 2), 2 Ogawa (Sp 2, 
Sp 3)
1 MGIT (Sp 2)
DST method MGIT SIRE MGIT SIRE Indirect LPA, LJ proportion LJ proportion LJ proportion Direct and indirect LPA
MTB=Mycobacterium tuberculosis. RIF=rifampicin. Sp1=sputum sample 1. Sp2=sputum sample 2. Sp3=sputum sample 3. ZN=light microscopy after Ziehl Neelsen staining of sputum smear. FM=conventional 
ﬂ uorescence microscopy after Auramine O staining. LPA=line-probe assay (direct: done from decontaminated sputum for smear-positive specimens; indirect: done from culture isolates for smear-negative 
specimens). MGIT=mycobacteria growth indicator tube. LJ=Löwenstein–Jensen. DST=drug-susceptibility testing. SIRE=streptomycin, isoniazid, rifampicin, ethambutol. *One smear was prepared from an 
NaOH-treated pellet (all patients) and one from a bleach-treated pellet (smear group only).
Table 1: Laboratory procedures
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Procedures
Our study was divided into two phases. In the validation 
phase, MTB/RIF test results were not reported or used for 
management of patients. This phase allowed the collection 
of baseline data and conﬁ rmed that the site could accurately 
undertake the MTB/RIF test. In the implementation phase, 
MTB/RIF test results informed tuberculosis treatment 
decisions. Before sites could move to the implementation 
phase they were required to meet predeﬁ ned performance 
targets, which were reviewed and approved by the 
institutional review boards. Table 1 shows the laboratory 
procedures used in every country. In both phases, partici-
pants provided 2–3 sputum samples as per local routine. 
One sample underwent smear microscopy and direct 
MTB/RIF testing, the second underwent smear microscopy, 
culture, and drug-susceptibility testing. The third sample 
was only collected at sites that routinely required three 
microscopy results for management of patients.
In South Africa, the routine use of bleach-pretreatment 
for ﬂ uorescent microscopy meant that MTB/RIF testing 
on the same sputum sample was not possible. Therefore, 
in South Africa we used a study design with weekly 
alternation between a baseline group and implementation 
group. In the baseline group, routine smear microscopy 
from a bleach-treated pellet was done, which was replaced 
by the MTB/RIF test (used for management of patients) 
in the implementation group. In both groups, a second 
specimen was obtained for smear microscopy from a 
sodium hydroxide (NaOH)-treated pellet, culture, and 
drug-susceptibility testing.
The MTB/RIF test was done on raw sputum samples 
with an automated readout provided to the user as 
described elsewhere.18 GeneXpert four-module devices 
were placed on an open bench in the microscopy area. On 
the basis of biosafety data,17 the MTB/RIF test sample 
preparation step was done applying the same local 
Figure 1: Study proﬁ le
MTB=Mycobacterium tuberculosis. RIF=rifampicin. MDR=multidrug resistant. DST=drug-susceptibility testing. *Some patients met several exclusion criteria and are listed 
more than once. †In South Africa only. ‡680 suspected cases of MDR tuberculosis were not included in the case-detection analysis to avoid patient-selection bias (patients 
were expected to have a higher tuberculosis prevalence and supposedly higher bacillary load); a subgroup analysis for these patients is shown in webappendix p 3.
7288 patients screened
640 did not provide two sputum samples
6648 eligible
6069 analysed
1327 patients without MTB/RIF
test results (baseline group)†
1033 culture positive
161 DST not done or
MTB/RIF test negative
750 rifampicin negative 122 rifampicin resistant 60 rifampicin negative 128 rifampicin resistant
45 DST not done or
MTB/RIF test negative
3029 culture negative 233 culture positive 447 culture negative
4062 suspected cases of tuberculosis
(case-detection analysis)
680 suspected cases of MDR tuberculosis‡
579 excluded*
 25 >7 days between collection of sputum sample one and two
 104 no culture done
 213 no valid culture result due to contamination
 14 no valid MTB/RIF test result
 207 smear positive, culture negative
 99 single positive culture with <20 colonies or >28 days
 11 culture-positive at follow-up only
 58 culture-positive but missing speciation
 132 culture-positive but non-tuberculous mycobacteria spp
 7 discrepant rifampicin on conventional drug-susceptibility testing
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biosafety conditions as for the preparation of microscopy 
smears: a biosafety cabinet was used at ﬁ ve of the nine 
sites. Temperature logs were placed at each facility to 
record the operating and reagent storage temperatures. 
Laboratory staﬀ  chosen as MTB/RIF test operators had 
little experience with laboratory methods other than 
smear microscopy, had never undertaken molecular 
testing, and had basic or no computer skills (see 
webappendix p 1). Masking, which was not necessary in 
South Africa due to study design, was accomplished at 
Lima, Peru Baku, Azerbaijan Cape Town, 
South Africa
Kampala, Uganda Vellore, India Manila, 
Philippines
Total
Characteristics of tuberculosis laboratories implementing the MTB/RIF test
Number of laboratories Three One Two One One One Nine
Level of health system Two health centres; 
one district hospital
MDR tuberculosis 
screening facility
One health centre; one 
provincial hospital
Emergency unit of 
referral hospital
Health centre MDR tuberculosis 
screening facility
··
Methods in routine use 
(during the study)
Health centres: ZN; 
district hospital: ZN, 
Ogawa
ZN, LJ, MGIT SIRE Health centre: FM; 
provincial hospital: FM
ZN ZN ZN, Ogawa, LJ ··
Mean MTB/RIF test operating 
temperature (range)
24°C (19–32°C) 21°C–AC (12–34°C) 22°C–AC (16–29°C) 25°C (20–32°C) 25°C–AC (19–42°C) 23°C–AC (19–25°C) ··
Median MTB/RIF test 
workload per day (range, IQR)
Health centre: 3 (1–16, 
2–4); district hospital: 
5 (1–15, 2–7)
8 (1–20, 3–12) Health centre: 5 (1–15, 
3–8); provincial 
hospital: 6 (1–24, 3–14)
2 (1–6, 1–3) 6 (1–20, 3–8) 5 (1–20, 3–7) 4 (1–24, 2–7)
Characteristics of study population
Estimated incidence of 
tuberculosis (new cases 
per 100 000) 
11322 11022 Health centre: 1622;23 
provincial 
hospital: 60024
29322 14525 12926 ··
Estimated MDR tuberculosis 
rate (new cases, 
retreatment cases)
5·3%, 23·6%27 22·3%, 55·8%28 3·3%, 7·7%29 1·1%, 11·7%30 2·4%, 17·4%28 3·8%, 20·9%31 ··
Estimated HIV co-infection 
rate in patients with 
tuberculosis
<3%32 5·6%33 76·1%19 31·9%30 7·0%25 <1%22 ··
Demographic characteristics of enrolled patients*
Number 1185 749 2522 372 902 918 6648
Enrolled in validation phase 
(controls)
1185/1185 (100%) 443/749 (59%) 1327/2522 (53%) 282/372 (76%) 896/902 (99%) 601/918 (65%) 4734/6648 (71%)
Enrolled in implementation 
phase
0/1185 306/749 (41%) 1194/2522 (47%) 90/372 (24%) 0/902 317/918 (35%) 1907/6648 (29%)
Median age (range, IQR) 37 (18–91, 26–53) 36 (18–74, 30–44) 36 (18–101, 29–46) 32 (18–79, 26–38) 45 (18–90, 32–58) 47 (18–95, 34–58) 38 (18–101, 29–50)
Women 578/1185 (49%) 1/749 (<1%) 1247/2522 (49%) 170/372 (46%) 274/902 (30%) 335/918 (36%) 2605/6648 (39%)
HIV status
Positive 5/1185 (<1%) 1/749 (<1%) 947/2522 (38%) 254/372 (68%) 40/902 (4%) 8/918 (<1%) 1255/6648 (19%)
Negative 289/1185 (24%) 609/749 (81%) 855/2522 (34%) 118/372 (32%) 4/902 (<1%) 9/918 (1%) 1884/6648 (28%)
Unknown 891/1185 (75%) 139/749 (19%) 720/2522 (29%) 0/372 858/902 (95%) 901/918 (98%) 3509/6648 (53%)
Diagnosis group at enrolment†
Group 1 (suspicion of drug-sensitive tuberculosis)
Patients 1092/1185 (92%) 644/749 (86%) 2372/2522 (94%) 363/372 (98%) 888/902 (98%) 503/918 (55%) 5862/6648 (88%)
Prevalence of tuberculosis‡ 177/1031 (17%) 229/578 (40%) 473/1968 (24%) 146/307 (48%) 101/837 (12%) 148/415 (36%) 1274/5136 (25%)
Prevalence of rifampicin 
resistance§
15/165 (9%) 46/224 (21%) 24/462 (5%) 4/130 (3%) 7/101 (7%) 48/134 (36%) 144/1216 (12%)
Group 2 (suspicion of MDR tuberculosis)
Patients 93/1185 (8%) 105/749 (14%) 150/2522 (6%) 9/372 (2%) 14/902 (2%) 415/918 (45%) 786/6648 (12%) 
Prevalence of tuberculosis 32/83 (39%) 17/99 (17%) 20/122 (16%) 1/8 (13%) 7/14 (50%) 168/328 (51%) 245/654 (37%)
Prevalence of rifampicin 
resistance 
8/27 (30%) 11/16 (69%) 5/20 (25%) 0/1 4/7 (57%) 113/142 (80%) 141/213 (66%)
Data are n/N (%), unless otherwise stated. MTB=Mycobacterium tuberculosis. RIF=rifampicin. MDR=multidrug resistant. ZN=light microscopy after Ziehl Neelsen staining of sputum smear. 
LJ=Löwenstein–Jensen. MGIT SIRE=mycobacteria growth indicator tube streptomycin, isoniazid, rifampicin, ethambutol. FM=conventional ﬂ uorescence microscopy after Auramine O staining. 
AC=air conditioning. *For 0·1% of enrolled patients, whether they were part of the validation or implementation phase was not reported. †Estimation based on epidemiological studies or surveys. ‡For 
calculations of prevalence of tuberculosis and rifampicin resistance, the exclusion criteria described in the methods section have been applied. §Calculations of rifampicin resistance prevalence were done only 
on the basis of patients who had rifampicin sensitivity testing.
Table 2: Characteristics of patients and study sites
See Online for webappendix
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the other sites by having diﬀ erent staﬀ  do smear 
microscopy and MTB/RIF testing.
The reference standard, quality-assured culture and 
drug-susceptibility testing, was done at reference 
laboratories located within 1 h of MTB/RIF test sites. 
Samples undergoing Löwenstein–Jensen or liquid culture 
(Bactec MGIT; BD Microbiology Systems, Cockeysville, 
MD, USA) were processed with standard N-acetyl-L-
cysteine–NaOH (2%) decontamination. For Ogawa 
culture, sputum specimens were decontaminated with 
the modiﬁ ed Petroﬀ  method.20 All positive cultures 
underwent MPT64-based (Capilia tuberculosis assay; 
Tauns, Numazu, Japan) species conﬁ rmation21 and, if 
positive for M tuberculosis, conventional drug-
susceptibility testing with Löwenstein–Jensen proportion 
or mycobacteria growth indicator tube (MGIT). In South 
Africa, the line-probe assay MTBDRplus (Hain 
Lifescience, Nehren, Germany) was done on NaOH-
treated pellets for smear-positive sputum and on culture 
isolates for smear-negative sputum. Conventional drug-
susceptibility testing was then used for specimens testing 
positive for drug-resistance-associated mutations. In 
Uganda, line-probe assay and, for 10% of culture positive 
patients (every tenth patient), Löwenstein–Jensen 
proportion was performed on MGIT isolates (except 
when only positive on Löwenstein–Jensen). HIV results 
were obtained from clinical records.
Clinicians categorised participants into two groups: 
patients who had suspected tuberculosis and presented for 
case detection and patients with suspected multidrug-
resistant tuberculosis who presented for resistance 
detection (patients who received tuberculosis treatment 
within the past year or had contact with multidrug-resistant 
tuberculosis). For analysis, patients with suspected 
tuberculosis were divided into four categories: smear-
positive and culture-positive pulmonary tuber culosis; 
smear-negative and culture-positive pulmonary tuber-
culosis; smear-negative, culture-negative and not treated 
(non-tuberculosis); and smear-negative and culture-
negative but treated for tuberculosis on the basis of clinical 
and radiological ﬁ ndings (clinical tuberculosis). A patient 
was regarded as having smear-positive tuber culosis on the 
basis of at least two scanty smears (1–9 bacilli per 100 ﬁ elds 
[1000× for light microscopy and 400× for ﬂ uorescence 
microscopy]) or one or more smears of grade 1+ or higher 
(10–99 bacilli per 100 ﬁ elds). A culture-positive case was 
deﬁ ned as the isolation of M tuberculosis in at least one 
culture. Patients who were culture-positive (suspected 
tuberculosis and multidrug-resistant tuberculosis) were 
categorised as sensitive or resistant to rifampicin.
Statistical analysis
We calculated sensitivity and speciﬁ city of the MTB/RIF 
test for each patient category stratiﬁ ed by HIV and smear 
microscopy status, and used the results of all microscopy 
and culture examinations to classify patients into the 
four groups. To prevent selection bias, patients with 
suspected multidrug-resistant tuberculosis were only 
included in the analysis of MTB/RIF test rifampicin-
detection endpoints.
We quantitatively assessed operational feasibility of 
introduction of the MTB/RIF test by examining indicators 
of robustness such as indeterminate rate, frequency of 
DNA contamination events, and variation of performance 
in time and between sites. We used a hands-on and 
question-based proﬁ ciency test and user-appraisal 
questionnaire to qualitatively establish the minimal 
training needs and ease of use. The Foundation for 
Innovative New Diagnostics (FIND; Geneva, Switzerland) 
study team did the training.
We assessed eﬀ ectiveness of every method by 
examining the time to detection of tuberculosis and 
rifampicin resistance and the time to reporting of results 
to the clinics. Additionally, we compared the time to 
treatment initiation from ﬁ rst sputum collection and the 
dropout rate (patients with conﬁ rmed tuberculosis who 
had not started treatment) between validation and 
implementation phases.
Within sites we measured association between 
variables with the Pearson’s χ² test and between sites we 
used the Cochran-Mantel-Haenszel statistic. We did 
within-patient analysis with McNemar’s test. We did a 
subgroup analysis for excluded patients. All analyses 
were done with SAS version 9.2, and p<0·05 was 
regarded as signiﬁ cant.
Role of the funding source
The FIND cosponsored the study and led study design, 
training, study coordination and monitoring, data 
analysis, and writing of the report. The other sponsors of 
the study had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
From Aug 11, 2009, until June 26, 2010, we enrolled 
6648 eligible adults (ﬁ gure 1, tables 2 and 3). One-oﬀ  
MTB/RIF testing correctly detected tuberculosis in more 
Culture positive Culture negative
Smear positive Smear negative Clinical tuberculosis Non-tuberculosis
Suspected cases of tuberculosis
HIV positive 86/648 (13%) 124/385 (32%) 392/2876 (14%) 19/153 (12%)
HIV negative 206/648 (32%) 129/385 (34%) 753/2876 (26%) 36/153 (24%)
HIV status unknown 356/648 (55%) 132/385 (34%) 1731/2876 (60%) 98/153 (64%)
Suspected cases of multidrug-resistant tuberculosis
HIV positive 0/195 3/38 (8%) 1/33 (3%) 54/414 (13%)
HIV negative 19/195 (10%) 9/38 (24%) 8/33 (24%) 127/414 (31%)
HIV status unknown 176/195 (90%) 26/38 (68%) 24/33 (73%) 233/414 (56%)
Table 3: HIV statuses in patients with suspected cases of tuberculosis and multidrug-resistant tuberculosis
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than 90% of patients with positive cultures, with 
99% speciﬁ city for non-tuberculosis (table 4). Perfor-
mance was much the same during validation and 
implementation phases (webappendix p 2). A one-oﬀ 
MTB/RIF test identiﬁ ed signiﬁ cantly (p<0·0001) more 
cases of tuber culosis than did 2–3 smear microscopy 
examinations per patient, which detected 699 of 
1041 culture-positive patients (sensitivity of 67·1%) and 
3700 of 3718 patients without tuberculosis (speciﬁ city 
of 99·5%). Although HIV co-infection signiﬁ cantly 
decreased the sensitivity of smear microscopy (p<0·0001), 
the sensitivity of MTB/RIF was not signiﬁ cantly aﬀ ected 
by HIV co-infection status (p=0·0849; table 5). MTB/RIF 
test sensitivity and speciﬁ city were much the same 
between basic health centres and sites with increased 
capacity both between countries (p=0·895 and p=0·097, 
respectively; webappendix p 2), and within countries with 
more than one site (webappendix p 2).
Sensitivity of MTB/RIF testing for smear-negative tuber-
culosis varied between countries (p<0·0001). It was lower 
at sites that used a reference standard of solid and liquid 
cultures (Azerbaijan, Uganda, and the Philippines) and 
slightly higher at sites that tested morning sputum samples 
rather than spot sputum collections (Peru and India).
MTB/RIF testing correctly identiﬁ ed 242 of 250 cases 
of rifampicin-resistant tuberculosis (sensitivity of 
96·8%) and 779 of 810 rifampicin-sensitive cases 
(speciﬁ city of 96·2%). However, because of concern over 
false-positive results, especially for settings with a low-
prevalence of multidrug-resistant disease, we changed 
the software cutoﬀ  deﬁ ning drug resistance during the 
study on May 12, 2010. With modiﬁ ed software 
deﬁ nitions, our post-hoc analysis showed that sensitivity 
decreased to 94·4% and speciﬁ city increased to 98·3% 
(table 6). 17 (6·8%) of 250 cases of rifampicin-resistant 
tuberculosis were sensitive to isoniazid.
24 (16%) of 153 patients with clinically diagnosed 
tuberculosis, but negative culture had positive results on 
MTB/RIF testing. 20 (83%) of these 24 patients had 
clinical and radiological follow-up, and all 20 improved 
on tuberculosis treatment. For the 118 (91%) of 
129 patients who tested negative on MTB/RIF but were 
treated for tuberculosis on the basis of a clinical diagnosis 
and had clinical and radiological follow-up, only 67 (57%) 
showed improvement (p<0·0001).
Median time to detection of tuberculosis for the MTB/
RIF test was 0 days (IQR 0–1), compared with 1 day (0–1) 
for smear microscopy, 30 days (23–43) for solid culture, 
Sensitivity Speciﬁ city (non-tuberculosis) Positive 
predictive 
value
Negative 
predictive 
value
All culture positive Sputum positive, culture positive Sputum negative, culture positive
Lima, Peru 171/177 (96·6%, 92·8–98·4) 134/135 (99·3%, 95·9–99·9) 37/42 (88·1%, 75·0–94·8) 825/828 (99·6%, 98·9–99·9) 98·0% 99·3%
Baku, Azerbaijan 203/229 (88·6%, 83·9–92·1) 135/138 (97·8%, 93·8–99·3) 68/91 (74·7%, 64·9–82·5) 303/307 (98·7%, 96·7–99·5) 97·6% 93·5%
Cape Town, South Africa 201/233 (86·3%, 81·3–90·1) 80/80 (100·0%, 95·4–100·0) 121/153 (79·1%, 72·0–84·8) 669/671 (99·7%, 98·9–99·9) 99·0% 95·6%
Kampala, Uganda 121/145 (83·4%, 76·6–88·6) 91/93 (97·8%, 92·5–99·4) 30/52 (57·7%, 44·2–70·1) 144/144 (100·0%, 97·4–100·0) 100·0% 87·7%
Vellore, India 101/101 (100·0%, 96·3–100·0) 70/70 (100·0%, 94·8–100·0) 31/31 (100·0%, 89·0–100·0) 671/687 (97·7%, 96·3–98·6) 85·8% 100·0%
Manila, Philippines 136/148 (91·9%, 86·4–95·3) 127/132 (96·2%, 91·4–98·4) 9/16 (56·3%, 33·2–76·9) 234/239 (97·9%, 95·2–99·1) 95·7% 95·9%
Total 933/1033 (90·3%, 88·4–92·0) 637/648 (98·3%, 97·0–99·0) 296/385 (76·9%, 72·4–80·8) 2846/2876 (99·0%, 98·5–99·3) 96·8% 96·8%
Data are number of positive results/number of samples tested (%, 95% CI). MTB=Mycobacterium tuberculosis. RIF=rifampicin.
Table 4: Sensitivity, speciﬁ city, and predictive values of a one-oﬀ  direct MTB/RIF test
HIV positive HIV negative HIV negative or unknown p value* 
Sensitivity in culture-positive samples
Smear microscopy 86/193 (44·6%, 37·7–51·6) 234/341 (68·6%, 63·5–73·3) 613/848 (72·3%, 69·2–75·2) <0·0001
MTB/RIF test 173/210 (82·4%, 76·7–86·9) 304/335 (90·7%, 87·2–93·4) 760/823 (92·3%, 90·3–94·0) 0·0849
Sputum positive 84/86 (97·7%, 91·9–99·4) 204/206 (99·0%, 96·5–99·7) 553/562 (98·4%, 97·0–99·2) 0·2167
Sputum negative 89/124 (71·8%, 63·3–78·9) 100/129 (77·5%, 69·6–83·9) 207/261 (79·3%, 74·0–83·8) 0·8976
Speciﬁ city in non-tuberculosis samples
Smear microscopy 660/660 (100·0%, 99·4–100·0) 1054/1060 (99·4%, 98·8–99·7) 3040/3058 (99·4%, 99·1–99·6) 0·2545
MTB/RIF test 389/392 (99·2%, 97·8–99·7) 748/753 (99·3%, 98·5–99·7) 2457/2484 (98·9%, 98·4–99·3) 0·2246
Data are number of positive results/number tested (%, 95% CI). On the basis of the p values, the performance of the MTB/RIF test in this study did not diﬀ er signiﬁ cantly in 
patients who were HIV positive compared with those who were HIV negative or who were not tested for HIV infection, while the sensitivity of smear microscopy was 
signiﬁ cantly reduced in patients who were HIV positive. MTB=Mycobacterium tuberculosis. RIF=rifampicin. *Determined by use of the Cochran-Mantel-Haenszel method 
comparing patients who are HIV positive with those whose statuses are HIV negative or unknown.
Table 5: Sensitivity and speciﬁ city of smear microscopy (two to three microscopy examinations as per routine practice) and a one-oﬀ  direct MTB/RIF test, 
stratiﬁ ed by HIV status of patients
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and 16 days (13–21) for liquid culture (ﬁ gure 2). Median 
time to detection of rifampicin resistance was 1 day (0–1) 
for the MTB/RIF test, 20 days (10–26) for line-probe 
assay (done directly from sputum pellet for smear-
positive specimens and from culture isolates for smear-
negative specimens) and 106 days (30–124) for phenotypic 
drug-susceptibility testing (ﬁ gure 2). Although MTB/
RIF testing and microscopy were done near the clinics 
and results were rapidly received by clinicians (median 
1 day [IQR 0–2] for MTB/RIF testing and 2 days [2–3] for 
microscopy), there were signiﬁ cant delays in receiving 
results from cultures (median 58 days [42–62]), line-
probe assays (40 days [27–53]), and conventional drug-
susceptibility testing (63 days [38–102]). Some results 
were lost or unreported (ﬁ gure 3).
Time between sputum collection and treatment 
initiation was very dependent on the testing method 
(ﬁ gure 4). In the baseline group in South Africa and the 
validation phase at other sites (ie, when MTB/RIF test 
results were not used to direct therapy), patients with 
smear-negative, culture-positive tuberculosis started 
treatment after a median of 56 days (IQR 39–81). Once 
MTB/RIF test results were used to direct therapy, 
the median time-to-treatment for smear-negative 
tuber culosis reduced to 5 days (2–8). Rates of un-
treated smear-negative, culture-positive tuber culosis 
reduced from 39·3% (95% CI 32·6–46·6) at baseline 
to 14·7% (9·9–21·2) after implemen tation of the 
MTB/RIF test.
GeneXpert provides an indeterminate result if 
unexpected results occur with any of the internal control 
measures. The MTB/RIF test was indeterminate 
in 126 (2%) of 5321 samples tested. 112 repeat tests were 
successful when adequate sputum remained, with the 
Sensitivity in rifampicin-resistant cases Speciﬁ city in rifampicin-sensitive cases Positive 
predictive value
Negative 
predictive value
Lima, Peru 22/23 (95·7%, 79·0–99·2) 161/162 (99·4%, 96·6–99·9) 95·6% 99·4%
Baku, Azerbaijan 47/50 (94·0%, 83·8–97·9) 160/161 (99·4%, 96·6–99·9) 98·0% 98·1%
Cape Town, South Africa 9/10 (90·0%, 59·6–98·2) 175/178 (98·3%, 95·2–99·4) 77·1% 99·3%
Kampala, Uganda 1/3 (33·3%, 6·1–79·2) 112/113 (99·1%, 95·2–99·8) 54·2% 97·9%
Vellore, India 8/10 (80·0%, 49·0–94·3) 91/93 (97·8%, 92·5–99·4) 80·5% 97·7%
Manila, Philippines 149/154 (96·8%, 92·6–98·6) 97/103 (94·2%, 87·9–97·3) 95·5% 95·9%
Total 236/250 (94·4%, 90·8–96·6) 796/810 (98·3%, 97·1–99·0) 93·2% 98·6%
Data are number of positive results/number tested (%, 95% CI). The reference standard was phenotypic susceptibility testing in Peru, Azerbaijan, Uganda, and the Philippines 
and genotypic testing by line-probe assay followed by phenotypic drug-susceptibility testing for resistant cases in South Africa and Uganda. MTB=Mycobacterium tuberculosis. 
RIF=rifampicin.
Table 6: MTB/RIF test sensitivity and speciﬁ city for detection of rifampicin resistance after change to software cutoﬀ 
Figure 2: Proportion of tuberculosis cases detected by each method in culture-positive patients
Percentages are the maximum proportion of cases detected by every method. (A) Tuberculosis case detection. (B) Detection of rifampicin resistance. Time to 
detection was deﬁ ned as time between date of sputum sample collection and date of positive result. MTB=Mycobacterium tuberculosis. RIF=rifampcicin.
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indeterminate rate reduced to less than 1% 
(14/5321 samples). In 1449 samples that were positive on 
MTB/RIF testing, 17 (1%) had indeterminate results for 
rifampicin resistance. These tests were not repeated. By 
comparison, the contamination rate was 441 (5%) of 
9690 cultures, including repeated cultures from re-
decontaminated pellets from all countries apart from 
South Africa and the Philippines.
Operators without previous molecular biology experience 
or computer skills passed proﬁ ciency testing after 1–3 days 
of training on MTB/RIF tests, including three hands-on 
runs. A 1 day online training was successfully used at two 
sites (Peru and Azerbaijan). Monthly variation in MTB/RIF 
test performance did not diﬀ er between sites (psensitivity=0·52 
on Cochran-Mantel-Haenszel test stratiﬁ ed by smear 
status and pspeciﬁ city=0·46 on χ²).
In one of the high HIV-prevalence sites, microscopy 
was introduced at the same time as MTB/RIF testing. 
Although MTB/RIF sensitivity for culture-positive 
tuberculosis at this site was much the same as in other 
centres (85·9%; 116 of 135 cases), the sensitivity of 
microscopy with one smear per patient was only 17·8% 
(21 of 118 smears) compared with 46·6% (55 of 118 smears) 
with a second smear at the reference laboratory. These 
ﬁ ndings support the laboratory managers’ perception, 
expressed in user appraisal questionnaires, that MTB/RIF 
test performance might be less dependent on user skills, 
motivation, or workload than is microscopy.
We did not detect any DNA contamination events 
during monthly negative control runs, and test speciﬁ city 
was high across sites. The four-module GeneXpert device 
was used for 1–24 tests a day with only two incidents 
needing product support (one network-card failure 
requiring device replacement and one module 
replacement). At four sites, the recorded operating 
temperatures exceeded the maximum recommended 
operating temperature (15–30°C) during more than 10% 
of runs. Test performance and frequency of indeterminate 
results did not show seasonal variation in these sites. In 
one case, the operating temperature exceeded 40°C and 
an error message appeared as described in the manual. 
Several sites had daily temperatures higher than the 
2–28°C recommended for cartridge storage temperature; 
cartridges were stored centrally and distributed twice 
every month. All sites had power cuts, but used 
uninterruptible power supplies to support the device 
during short power cuts and one site used an inverter 
and serial car batteries during a longer power outage.
Discussion
The MTB/RIF test assay was designed speciﬁ cally for use 
close to point-of-treatment in endemic disease settings, 
and is the ﬁ rst of a new generation of diagnostic tests 
that have the potential to bring highly sensitive nucleic 
acid ampliﬁ cation testing to peripheral sections of the 
health system (panel). In our large multicentre study, 
MTB/RIF testing in subdistrict microscopy facilities by 
Figure 3: Proportion of results reported to the clinics for each  method from date of ﬁ rst sputum sample
Percentages are the maximum proportion of results received by the clinic within 30 days of recorded date of 
smear microscopy, MTB/RIF test, or culture, or within 150 days of sputum collection for drug-susceptibility 
testing (DST). TB=Mycobacterium tuberculosis. RIF=rifampcicin.
Figure 4: Time to treatment during validation phase (treatment based on 
conventional methods only) and implementation phase (treatment based 
on MTB/RIF test and conventional methods) for patients with 
smear-positive, culture-positive tuberculosis, smear-negative, 
culture-positive tuberculosis, or multidrug-resistant tuberculosis
Box plots show median time to treatment (black line), mean (dashed black 
line), 25th and 75th percentiles, and minimum and maximum reported time 
to treatment (whiskers). Time to treatment was calculated from the date of 
ﬁ rst sputum collection to the date of treatment initiation. For the time to 
multidrug-resistant treatment, treatment decisions during this study were 
only made on the basis of routine drug-susceptibility testing methods. 
MTB=Mycobacterium tuberculosis. RIF=rifampcicin. 
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routine staﬀ  with minimal training retained the accuracy 
seen in previous controlled studies that were undertaken 
in reference centres.18,19,34–36 Previous studies of the 
MTB/RIF test that assessed either sputum samples or 
concentrated, decontaminated sputum pellets, have 
consistently reported test sensitivity of 72–75% in cases 
of smear-negative tuberculosis and 98–100% in cases of 
smear-positive tuberculosis.18,19,34–36 One small retrospective 
study of 28 frozen pellets reported a sensitivity of 57% for 
cases of smear-negative tuberculosis.35 In our study, a 
one-oﬀ  direct MTB/RIF test detected tuberculosis in 
more than 90% of patients who were culture positive, 
including nearly 77% of those with negative smears. The 
robustness of these data suggests that the test can be 
used in various resource-scarce settings for case detection 
and for rapid decentralised screening of multidrug-
resistant tuberculosis. The ability to rapidly detect smear-
negative tuberculosis in peripheral settings, including 
among patients with HIV, is a breakthrough in 
tuberculosis care and control.
This is the ﬁ rst study in which MTB/RIF test results have 
been made available to clinic staﬀ  to inform patient 
management, and hence the ﬁ rst to describe the eﬀ ect on 
time to detection and treatment. The short turnaround 
time resulted in substantially faster initiation of appropriate 
tuberculosis therapy, particularly for patients with smear-
negative disease, and lower dropout rates. Many patients 
with tuberculosis drop out during the diagnostic process 
through failing to submit specimens for microscopy 
when prescribed,37 submitting an initial specimen but not 
returning,38 or not receiving or acting on positive test 
results.39–41 Rapid testing, even if less sensitive than slower 
methods, can result in more patients being correctly 
treated. Overall, patient dropout with one-oﬀ  MTB/RIF 
testing could possibly be reduced even further in routine 
conditions, as our analysis excluded 640 (9%) of 
7288 enrolled patients who did not provide a second sample 
(ﬁ gure 1). Although treatment decisions for multidrug-
resistant tuberculosis were not informed by MTB/RIF test 
results, delays in result reporting for rapid, but centralised 
drug-susceptibility testing (line-probe assay and MGIT 
drug-susceptibility testing) were substantially shortened by 
decentralised MTB/RIF testing, and would probably 
translate into reduced time-to-appropriate-treatment.
Although the sensitivity and speciﬁ city of MTB/RIF 
test for detection of rifampicin resistance in this study 
was high (94·4% sensitivity and 98·3% speciﬁ city), 
accuracy was higher in previous publications (99–100% 
sensitivity and 100% speciﬁ city after discordant resolution 
by genotyping).18,19,34–36 Assay development partners are 
working to further improve MTB/RIF test accuracy of 
detection of multidrug-resistant tuberculosis. The low 
positive-predictive value of MTB/RIF for rifampicin 
resistance detection that we noted in patients with a low 
pretest probability of multidrug-resistant tuberculosis 
might justify the need for conﬁ rmatory testing with 
conventional methods in such settings.
Several issues might restrict the applicability of the 
MTB/RIF test at small health centres. The device requires 
stable electricity supply, although some centres 
successfully tested battery operation. Device deployment 
above 30°C is presently not recommended by the 
manufacturer and cartridges are conﬁ rmed as stable at 
2–28°C (eﬀ orts are ongoing to increase the operating and 
storage temperatures). There were few device breakdowns 
in this study as the devices used were new, and there are 
no data for their extended use in dusty and humid 
conditions. The GeneXpert device needs calibration 
yearly, which requires either access to an MTB/RIF test 
distributor or internal capacity to replace modules as per 
manufacturer instructions.
In the study, MTB/RIF test cartridges were handled 
with the same level of biosafety as microscopy. As the 
MTB/RIF tuberculosis assay was designed to keep 
biohazards to a minimum, the risk should be 
substantially lower than that noted in microscopy. As 
published elsewhere,17 the only specimen processing 
required is the addition of a sample reagent that is 
bactericidal and results in a 10⁷ reduction in viable 
Panel: Research in context
Systematic review
We searched the PubMed database for studies about the 
Xpert MTB/RIF test published in English up to March 18, 
2011, with the search terms “Xpert” or “GeneXpert” and 
“tuberculosis”. We did not identify any systematic reviews. 
We identiﬁ ed ﬁ ve studies reporting on performance of 
the MTB/RIF test for detection of tuberculosis in 
respiratory specimens.
Interpretation
All studies that we identiﬁ ed were done in research or referral 
laboratories and were small,18,34–36 apart from one large 
multicentre assessment.19 Most included testing of previously 
collected archived samples. In these studies, the reported 
sensitivity of the MTB/RIF test for detection of smear-positive 
tuberculosis (98–100%) and smear-negative tuberculosis 
(72–75%) were consistent, apart from one small study that 
documented a sensitivity of 57% for smear-negative 
tuberculosis in 28 previously frozen sputum pellets. With 
regard to detection of rifampicin resistance, sensitivity and 
speciﬁ city were very high in all previous studies (99–100% 
sensitivity and 100% speciﬁ city after resolution of discordant 
cases by genotyping), although numbers of rifampicin-
resistant cases were small in all studies apart from 
multicentre assessment. Our study conﬁ rms the sensitivity of 
the MTB/RIF test for smear-positive and smear-negative 
tuberculosis, when undertaken in routine microscopy centres, 
and showed reduced, but good, performance for detection of 
rifampicin resistance. Furthermore, we suggest the MTB/RIF 
test can provide a substantially reduced time to detection and 
treatment for smear-negative tuberculosis.
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mycobacteria in the ﬁ rst 15 min. Additionally, unlike 
smear microscopy, the manual pipetting steps and the 
automated portion of the assay do not generate viable 
mycobacterial aerosols.17 Together, these results suggest 
that the MTB/RIF test can be done without special 
biosafety precautions.
Our study ﬁ ndings have several limitations. The use 
of diﬀ erent study designs and diagnostic algorithms 
across sites made a direct comparison of ﬁ ndings 
challenging. Our study did not allow us to determine 
the eﬀ ect of rapid and early detection on the number of 
patients treated and on treatment outcomes, as longterm 
follow-up was not undertaken and as the parallel use of 
culture, not otherwise routinely available, may have 
aﬀ ected physicians’ choices. Additionally, the study did 
not include any testing of close contacts to measure 
eﬀ ect on transmission. Participating sites were urban or 
periurban and supply chain manage ment, reagent 
storage, and calibration are likely to be more problematic 
in rural areas.
Overall, our ﬁ ndings suggest that decentralised 
MTB/RIF test implementation is feasible and could lead 
to an improvement in tuberculosis care and control. Any 
improvement will require increased detection of 
tuberculosis and multidrug-resistant-tuberculosis to 
coincide with scale-up of ﬁ rst-line, and more importantly, 
second-line treatment.42 Whether early and appropriate 
treatment after MTB/RIF testing can reduce tuberculosis-
associated morbidity and mortality, and its eﬀ ect on 
transmission, needs to be established.
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